September 10 - 12, 2020   Virtual Event

Non-CME Educational Activities

All events are scheduled during times that do not conflict with Symposium CME educational programing.

These optional non-CME educational activity and are not approved for CME or continuing education credit. The content of these optional non-CME activities and opinions expressed by presenters are those of the sponsor or presenters.

All times listed are Central Time Zone.


Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

Thursday, September 10, 2020 • 8:15 a.m. - 8:45 a.m.

Sponsored by Immunomedics


A Treatment Option for Patients With HR+, HER2- Advanced or Metastatic Breast Cancer

Thursday, September 10, 2020 • 11:35 a.m. - 12:05 p.m.

Sponsored by Lilly


Innovative Oral Treatment Options for Patients: HR+/HER2- mBC or gBRCA-Mutated Triple-Negative and HR+/HER2- mBC

Friday, September 11, 2020 • 7:45 a.m. - 8:45 a.m.

Sponsored by Pfizer


TUKYSATM (tucatinib): A NEW TREATMENT OPTION for patients with HER2+ Metastatic Breast Cancer (MBC)

Friday, September 11, 2020 • 12:05 p.m. - 12:35 p.m.

Sponsored by Seattle Genetics


Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-Her2 Therapies

Saturday, September 12, 2020 • 8:15 a.m. - 8:45 a.m.

Sponsored by Daiichi Sankyo


Navigating the HER2+ Breast Cancer Treatment Landscape: A Case-Based Clinical Discussion

Saturday, September 12, 2020 • 12:05 p.m. - 12:35 p.m.

Sponsored by Genentech

© 2021 Robert H. Lurie Comprehensive Cancer Center